Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2a multicenter, randomized study titled A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease. The study aims to evaluate the effectiveness and safety of targeted therapies for adults with moderate to severe Crohn’s Disease, a chronic inflammatory condition of the digestive tract.
The study tests several interventions, including Risankizumab, ABBV-382, and Lutikizumab, which are administered through subcutaneous injections or intravenous infusions. These therapies are designed to reduce inflammation and manage symptoms in Crohn’s Disease patients.
The study employs a randomized, sequential intervention model without masking, primarily focusing on treatment. Participants are divided into groups to receive different combinations of the drugs, with a 12-week induction period, a 12-week maintenance period, and an optional long-term extension.
The study began on September 4, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 23, 2025, indicating ongoing recruitment.
This clinical study could significantly impact AbbVie’s stock performance and investor sentiment, especially if the results demonstrate efficacy and safety. As the pharmaceutical industry is highly competitive, positive outcomes could enhance AbbVie’s market position against competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.